0001453687-23-000092.txt : 20231201 0001453687-23-000092.hdr.sgml : 20231201 20231201164308 ACCESSION NUMBER: 0001453687-23-000092 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 EFFECTIVENESS DATE: 20231201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc. CENTRAL INDEX KEY: 0001453687 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-498655 FILM NUMBER: 231460175 BUSINESS ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-923-1400 MAIL ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC DATE OF NAME CHANGE: 20090109 D 1 primary_doc.xml X0708 D LIVE 0001453687 Cartesian Therapeutics, Inc. 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 617-923-1400 DELAWARE SELECTA BIOSCIENCES INC Corporation true Carsten Brunn 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Executive Officer Blaine Davis 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Executive Officer Carrie S. Cox 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Director Timothy Barabe 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Director Nishan De Silva 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Director Murat Kalayoglu 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Director Aymeric S. Sallin 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Director Michael Singer 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Director Patrick S. Zenner 704 Quince Ochard Road Gaithersburg MD MARYLAND 20878 Director Biotechnology Decline to Disclose 06b false 2023-11-13 false true convertible preferred stock convertible into common stock true 0 60250000 60250000 0 false 2 0 0 0 false Cartesian Therapeutics, Inc. /s/ Blaine Davis Blaine Davis Chief Financial Officer 2023-12-01